Globally, 90 per cent of participants have detectable antibodies up to seven months post contracting COVID-19.
Next, the research team evaluated the function of these antibodies, i.e. their neutralizing activity against the virus SARS-CoV-2.
Also, the research team analysed the neutralizing capacity of the antibodies produced by the patients and volunteers.
“Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2,” Veldhoen said.
Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2.